VAERS Explorer
Back to explore

Report #2850283

Received Jul 18, 2025

Office visit
A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
Age unknown
State
IA
Recovered
Unknown
Vaccinated
Apr 7, 2025
Onset
Jun 24, 2025
Days to onset
78
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HEPHEP B (HEPLISAV-B)DYNAVAX TECHNOLOGIES CORPORATION1945660IM / LA

Symptoms (1)

Extra dose administered

Symptom narrative

Extra Dose Administered; Gave HEPLISAV-B Series Two Doses 28 Days Apart, Rechecked Titer and He is Non-Reactive; Initial report received on 07-Jul-2025. A nurse reported that a 33-year-old male received three doses of HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization and had a titer lab test which showed that he is non-reactive. No concomitant medications or medical history was reported. On 07-Apr-2025, the patient received dose 1 of a hepatitis B vaccine HEPLISAV-B (lot number 945660 and expiration date 31-Jan-2027; NDC number not available) intramuscularly in the left deltoid. On 12-May-2025, the patient received dose 2 of a hepatitis B vaccine HEPLISAV-B (lot number 945664 and expiration date 31-Jan-2027; NDC number not available) intramuscularly in the left deltoid. On 24-Jun-2025, 44 days after receiving the second dose of HEPLISAV-B, the patient had a qualitative hepatitis B surface antibody titer test performed. The test result showed non-reactive (not immune to hepatitis B virus infection). On 09-Jul-2025, 59 days after receiving the second dose of HEPLISAV-B, the patient received dose 3 of a hepatitis B vaccine HEPLISAV-B (lot number 946060 and expiration date 05-May-2027; NDC number not available) intramuscularly in the left deltoid. No additional information was reported. Company Comment: The company assessed the events as non-serious. The event of vaccination failure was considered not immunologically confirmed based on the dosing schedule.; Sender's Comments: The company assessed the events as non-serious. The event of vaccination failure was considered not immunologically confirmed based on the dosing schedule.

Lab data

Test Date: 20250331; Test Name: Hepatitis B Surface Antibody, Qualitative; Test Result: Negative ; Comments: Non Reactive; Test Date: 20250624; Test Name: Hepatitis B Surface Antibody, Qualitative; Test Result: Negative ; Comments: Non Reactive